Abstract
Baseline disease-modifying therapies (DMTs) for multiple sclerosis (MS) include three different preparations of interferonbeta (IFN-β) and glatiramer acetate (GA). These substances reduce relapse rates, side-effects are tolerated by most patients and - after more than 15 years of experience - the long-term safety profile for these drugs can be appraised as very good. In 2006, the therapeutic tool kit was augmented by the first monoclonal antibody, natalizumab, approved as monotherapy for treatment-refractory highly active MS. The restriction to these patient groups results from the rare, but fatal risk of JC virus-induced progressive multifocal leukoencephalopathy (PML). The first oral agent (fingolimod) was approved in 2010 for the United States and in 2011 for Europe. As a further option for therapy escalation the chemotherapeutic agent mitoxantrone is approved for non-responding relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS). The use of mitoxantrone is limited by severe cardiotoxicity and the risk of treatment related acute leukemia.
However, despite the fact that therapeutic options for MS have significantly been widened over the past decade new treatment options and more convenient modes of application are needed to enhance efficacy and improve adherence to therapy. This article will review recent developments in MS treatments focusing on oral agents (cladribine, fingolimod, BG00012, teriflunomide and laquinimod) and novel monoclonal antibodies (alemtumzumab, daclizumab, ocrelizumab, ofatumumab).
Keywords: Multiple sclerosis, cladribine, fingolimod, BG00012, laquinimod, teriflunomide, alemtuzumab, daclizumab, disease-modifying therapies (DMTs), IFN β.
Current Pharmaceutical Design
Title:Immune Therapy of Multiple Sclerosis - Future Strategies
Volume: 18 Issue: 29
Author(s): Sven G. Meuth, Kerstin Gobel and Heinz Wiendl
Affiliation:
Keywords: Multiple sclerosis, cladribine, fingolimod, BG00012, laquinimod, teriflunomide, alemtuzumab, daclizumab, disease-modifying therapies (DMTs), IFN β.
Abstract: Baseline disease-modifying therapies (DMTs) for multiple sclerosis (MS) include three different preparations of interferonbeta (IFN-β) and glatiramer acetate (GA). These substances reduce relapse rates, side-effects are tolerated by most patients and - after more than 15 years of experience - the long-term safety profile for these drugs can be appraised as very good. In 2006, the therapeutic tool kit was augmented by the first monoclonal antibody, natalizumab, approved as monotherapy for treatment-refractory highly active MS. The restriction to these patient groups results from the rare, but fatal risk of JC virus-induced progressive multifocal leukoencephalopathy (PML). The first oral agent (fingolimod) was approved in 2010 for the United States and in 2011 for Europe. As a further option for therapy escalation the chemotherapeutic agent mitoxantrone is approved for non-responding relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS). The use of mitoxantrone is limited by severe cardiotoxicity and the risk of treatment related acute leukemia.
However, despite the fact that therapeutic options for MS have significantly been widened over the past decade new treatment options and more convenient modes of application are needed to enhance efficacy and improve adherence to therapy. This article will review recent developments in MS treatments focusing on oral agents (cladribine, fingolimod, BG00012, teriflunomide and laquinimod) and novel monoclonal antibodies (alemtumzumab, daclizumab, ocrelizumab, ofatumumab).
Export Options
About this article
Cite this article as:
G. Meuth Sven, Gobel Kerstin and Wiendl Heinz, Immune Therapy of Multiple Sclerosis - Future Strategies, Current Pharmaceutical Design 2012; 18 (29) . https://dx.doi.org/10.2174/138161212802502198
DOI https://dx.doi.org/10.2174/138161212802502198 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Sclerosis – Established and Novel Therapeutic Approaches
Central Nervous System Agents in Medicinal Chemistry Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Gas Chromatography-electron Capture Detection Method for Determination of Polyols in the Urine
Current Organic Chemistry Therapeutic Targeting of Leukocyte Trafficking Across the Blood-Brain Barrier
Inflammation & Allergy - Drug Targets (Discontinued) Mouse Models of Multiple Sclerosis: Lost in Translation?
Current Pharmaceutical Design Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Pharmacogenomics – Implications in the Development of HIV-Associated Brain Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adult-Onset Genetic Leukoencephalopathies. Focus on the More Recently Defined Forms
Current Molecular Medicine Graphene-based Biosensors for Biomolecules Detection
Current Nanoscience Plasmodium Drug Targets Outside the Genetic Control of the Parasite
Current Pharmaceutical Design Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Is High Oral Dose L-arginine Intake Effective in Leukoaraiosis? Preliminary Data, Study Protocol and Expert’s Opinion
Current Aging Science Neurological Involvement in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets